Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of iptacopan in adults with acetylcholine receptor antibody-positive generalized myasthenia gravis
MOH_2024-08-14_013586Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Iptacopan + stable standard of care, Placebo + stable standard of care and Open-label extension iptacopan (3 arms). Planned start Jun 2024; status: not yet recruiting.
02
Drugs
Iptacopan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2024-08-14_013586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-14_013586.